OCUGEN INC. - COMMON STOCK

Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results

29 Jul 2022 07:30:58 By Nasdaq GlobeNewswire

Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases

21 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’

14 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy

13 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Ocugen, Inc. to Present at BIO International Convention 2022

09 Jun 2022 18:17:10 By Nasdaq GlobeNewswire

Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

24 May 2022 07:11:00 By Nasdaq GlobeNewswire

Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference

23 May 2022 07:34:00 By Nasdaq GlobeNewswire

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)

23 May 2022 06:36:00 By Nasdaq GlobeNewswire

Ocugen Provides Business Update and First Quarter 2022 Financial Results

06 May 2022 06:33:00 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results

02 May 2022 07:37:00 By Nasdaq GlobeNewswire

Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

29 Apr 2022 11:36:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial

25 Apr 2022 07:33:00 By Nasdaq GlobeNewswire

Ocugen, Inc. to Present at NobleCon18

19 Apr 2022 17:32:00 By Nasdaq GlobeNewswire

Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America

18 Apr 2022 07:11:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)

12 Apr 2022 08:31:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

01 Apr 2022 07:37:00 By Nasdaq GlobeNewswire

Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors

23 Mar 2022 07:44:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance

21 Mar 2022 18:36:00 By Nasdaq GlobeNewswire

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

18 Mar 2022 17:56:00 By Nasdaq GlobeNewswire

Ocugen, Inc. to Present at the 34th Annual ROTH Conference

09 Mar 2022 07:11:00 By Nasdaq GlobeNewswire